22.01.2010 • NewsIntercellGlaxoSmithKline (GSK)GSK

Intercell, GSK team up for Patch Vaccines

Britain's Glaxosmithkline said it was teaming up with Austrian vaccine maker Intercell to develop patch vaccines that can be delivered without needles. GSK will make an up-front cash contribution of €33.6 million and an equity investment of up to €84 million via staggered share purchases of up to 5% of the company. The deal will include Intercell's candidate vaccine for travellers' diarrhea, which is currently in final stage clinical trials, and a potential single application pandemic flu vaccine which is in Phase II trials. The firms said they would also be exploring the use of the patch technology for other vaccines in GSK's portfolio.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.